Clinical experience with tigecycline in the treatment of nosocomial infections caused by isolates exhibiting prevalent resistance mechanisms;Experiencia clínica con tigeciclina en el tratamiento de infecciones nosocomiales producidas por aislados con mecanismos de resistencia prevalentes

Revista Espanola de Quimioterapia

Volumn 22, Issue 1, 2009, Pages 48-56

  Gimenez M J ^a   Garcia Rey C ^a   Barberan J ^b   Aguilar, Lorenzo ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Multidrug resistant; Nosocomial infections; Tigecycline

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; COMORBIDITY; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; MALIGNANT NEOPLASTIC DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; REVIEW; SEPSIS; SEPTIC SHOCK; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MINOCYCLINE;

EID: 68549107681     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Cuevas O, Cercenado E, Bouza E, Castellares C, Trincado P, Cabrera R, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin Microbiol Infect 2007;13:250-256
2. Cuevas O, Cercenado E, Goyanes MJ, Vindel A, Trincado P, Boquete T, et al. Staphylococcus spp. En Espana: situación actual y evolution de la resistencia a antimicrobianos (1986-2006). Enferm Infecc Microbiol Clin 2008;26:269-277
3. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003;47:3040-3045 (Pubitemid 37229554)
4. Khosrovaneh A, Riederer K, Saeed S, Tabriz MS, Shah AR, Hanna MM, et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteriemia. Clin Infect Dis 2004;38:1328-1330 (Pubitemid 38608580)
5. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-1215
6. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteriemia. Clin Infect Dis 2008;46:193-200.
7. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42 Suppl 1:S13-24.
8. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008;27:3-15. (Pubitemid 350197870)
9. Oteo J, Cuevas O, Navarro C, Aracil B, Campos J; Spanish Group of The European Antimicrobial Resistance Surveillance System (EARSS). Trends in antimicrobial resistance in 3469 enterococci isolated from blood (EARSS experience 2001-2006, Spain): increasing ampicillin resistance in Enterococcus faecium. J Antimicrob Chemother 2007;59:1044-1045
10. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007;7:29.
11. Saribas S, Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy. 2004;50:250-254
12. Sánchez-Romero I, Cercenado E, Cuevas O, García-Escribano N, García-Martínez J, Bouza E; Spanish Group for Study of Pseudomonas aeruginosa. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003). Rev Esp Quimioter. 2007;20:222-229
13. Pascual A, Perea E, Álvarez M, Casal M, García de Lomas J, García Rodríguez JA, et al. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. Diagn Microbiol Infect Dis 2007;57:195-200.
14. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 2007;13:1192-1198 (Pubitemid 350063644)
15. Romero ED, Padilla TP, Hernández AH, Grande RP, Vázquez MF, García IG, et al. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2007;59:433-437
16. Sorlózano A, Gutiérrez J, Salmerón A, Luna JD, Martínez-Checa F, Román J, et al. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006;28:532-536 (Pubitemid 44779174)
17. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST) Group. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005;52:173-179
18. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52:215-227
19. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase- producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50:2695-2699 (Pubitemid 44198689)
20. Hope R, Warner M, Potz NA, Fagan EJ, James D, Livermore DM. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006;58:1312-1314 (Pubitemid 44884164)
21. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-573 (Pubitemid 351170830)
22. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005;49:1017-1022 (Pubitemid 40327718)
23. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-978
24. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001;45:3375-3380 (Pubitemid 33107849)
25. Food and Drug Administration. En: www.fda.gov
26. EUCAST. En: www.escmid.org
27. Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2007;60:1406-1407
28. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-1029 (Pubitemid 47617749)
29. BSAC. Methods for Antimicrobial Susceptibility Testing http://www.bsac.org.uk/-db/-documents/version-7-1-february-2008.pdf (consultado el 23 de julio de 2008).
30. Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. In vitro Activity of Tigecycline Against Gram-positive and Gram-negative Pathogens as Evaluated by Broth Microdilution and E-test. J Clin Microbiol 2008;46:2862-2867
31. Betriu C, Culebras E, Gómez M, Rodríguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005;56:349-352
32. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.Antimicrob Agents Chemother 2007;51:1649-1655
33. Giménez MJ, Barberán J, Aguilar L. Eficacia terapéutica, modelos animales y farmacodinamia experimental: ¿qué datos conocemos de la tigeciclina? Rev Esp Quimioterap 2007;20:387-394
34. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-171
35. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-229 (Pubitemid 40065796)
36. Agencia Española de Medicamentos y Productos Sanitarios (AGE-MED). En: www.agemed.es
37. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-1945 (Pubitemid 46903077)
38. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008;52:204-210 (Pubitemid 46903077)
39. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-1632 (Pubitemid 40463407)
40. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-1229 (Pubitemid 44884142)
41. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55. (Pubitemid 351865873)
42. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-570 (Pubitemid 351263497)
43. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008;14:512-514
44. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 2007;27:456-458
45. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteriemia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-987
46. Curcio D, Fernández F, Duret F. Tigecycline use in critically ill older patients: case reports and critical analysis. J Am Geriatr Soc 2007;55:312-313 (Pubitemid 46184415)
47. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-1201 (Pubitemid 47173663)
48. Leclerc T, Perez JP, Debien B, Clapson P, Lenoir B. Traitement d'un shock septique à Acinetobacter baumannii multirésistant par tigécycline en association. Ann Fr Anesth Reanim 2007;26:1056-1058
49. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006;25:257-260 (Pubitemid 43800546)
50. Gallagher JC, Rouse HM. Tigecycline for the Treatment of Acinetobacter Infections: A Case Series September. Ann Pharmacother 2008;42:1188-1194
51. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-131 (Pubitemid 46017915)
52. Sopirala MM, Pope-Harman A, Nunley DR, Moffatt-Bruce S, Ross P, Martin SI. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant 2008;27:804-807
53. Curcio D, Fernández F, Duret F. Uso inicial de tigeciclina en Argentina. Rev Chil Infect 2007;24:497-499
54. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007;27:1052-1057
55. Evagelopoulou P, Myrianthefs P, Markogiannakis A, Baltopoulos G, Tsakris A. Multidrug-resistant Klebsiella pneumoniae mediastinals safely and effectively treated with prolonged administration of tigecycline. Clin Infect Dis 2008;46:1932-1933
56. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteriemias. J Chemother 2007;19:232-233
57. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, et al. Use of tigecycline for the treatment of prolonged bacteriemia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008;60:319-322 (Pubitemid 351255574)
58. Krueger WA, Kempf VA, Peiffer M, Nagele U, Unertl KE, Schroeder TH. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum- beta-lactamase-producing Escherichia coli. J Clin Microbiol 2008;46:817-820 (Pubitemid 351231347)
59. Cobo J, Morosini MI, Cantón R. Commentary on manuscript: Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis. 2008;61:360-361 (Pubitemid 351847792)
60. Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis 2008;61:358-359 (Pubitemid 351858573)
61. Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 2007;19:753-754 (Pubitemid 351212030)
62. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol 2008;46: 1892-1893 (Pubitemid 351657253)
63. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67.
64. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intraabdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005;5:88.
65. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006;38:1081-1084 (Pubitemid 44869284)
66. Saner FH, Heuer M, Rath PM, Gensicke J, Radtke A, Drühe N, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transpl 2006;12:1689-1692 (Pubitemid 44742550)
67. Khanna N, Inkster T. Meticillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline. J Clin Pathol 2008;61:967-968
68. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53.
69. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-4666 (Pubitemid 41552597)
70. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-261 (Pubitemid 41196869)
71. Swoboda S, Hoppe-Tichy T, Geiss HK, Hainer C, Nguyen TH, Knaebel HP, et al. Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy. Anaesthesist 2007;56:169-174 (Pubitemid 46333001)
72. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-344 (Pubitemid 350020012)
73. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008;61:729-733 (Pubitemid 351321153)